NASDAQ:RPRX - Nasdaq - GB00BMVP7Y09 - Common Stock - Currency: USD
RPRX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 199 industry peers in the Pharmaceuticals industry. While RPRX belongs to the best of the industry regarding profitability, there are concerns on its financial health. RPRX is cheap, but on the other hand it scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 4.71% | ||
ROE | 12.37% | ||
ROIC | 6.02% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 57.1% | ||
PM (TTM) | 37.95% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.95 | ||
Debt/FCF | 28.91 | ||
Altman-Z | 1.59 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.44 | ||
Quick Ratio | 1.44 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 7.85 | ||
Fwd PE | 7.03 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 70.24 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.75% |
32.2
+0.17 (+0.53%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.75% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 7.85 | ||
Fwd PE | 7.03 | ||
P/S | 8.17 | ||
P/FCF | 70.24 | ||
P/OCF | 6.68 | ||
P/B | 2.66 | ||
P/tB | 2.66 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 4.71% | ||
ROE | 12.37% | ||
ROCE | 7.62% | ||
ROIC | 6.02% | ||
ROICexc | 6.72% | ||
ROICexgc | 6.72% | ||
OM | 57.1% | ||
PM (TTM) | 37.95% | ||
GM | N/A | ||
FCFM | 11.63% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.95 | ||
Debt/FCF | 28.91 | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | 110.7% | ||
Interest Coverage | -8.1 | ||
Cash Conversion | N/A | ||
Profit Quality | 30.65% | ||
Current Ratio | 1.44 | ||
Quick Ratio | 1.44 | ||
Altman-Z | 1.59 |